GGrantIndex
Sort

51,593 grants matching hepatitis

HBV Prevention for Homeless At-Risk for HBV/HCV/HIV

$791,514
Adeline M Nyamathi · University Of California Los Angeles · R01 · FY2006 · DA

Mechanisms of repeated control of acute hepatitis C infection in humans

$791,478
Andrea L Cox · Johns Hopkins University · U19 · FY2016 · AI

CARE Corrections: Technology for Jail HIV/HCV Testing, Linkage, and Care (TLC)

$791,350
Curt G Beckwith · Miriam Hospital · R01 · FY2010 · DA

Correlates of protective immunity to HCV and rational vaccine design: Project 2

$791,335
Arash Grakoui · Emory University · U19 · FY2023 · AI

NOVEL STRATEGIES TO IMPROVE LIVER CANCER SURVEILLANCE UPTAKE AND EARLY DETECTION

$791,318
Anna Sf Lok · University Of Michigan At Ann Arbor · U01 · FY2020 · CA

FUNCTIONAL GENOMICS & VIROLOGY CORE

$791,307
Michael G Katze · University Of Washington · P30 · FY2007 · DA

Pharmacogenetics of the Statin Response

$791,279
Tufts University Boston · R01 · FY2004 · HL

Asian Community Cancer Health Disparities Center (ACCHDC)

$790,949
Grace X Ma · Temple Univ Of The Commonwealth · U54 · FY2014 · CA

Characterization of silently HBV-infected hepatocytes in HIV co-infection

$790,878
Ashwin Balagopal · Johns Hopkins University · R01 · FY2020 · AI

Long Acting Beta Interferon for Treating Multiple Sclerosis - Phase II Continuing

$790,800
George Norbert Cox · Bolder Biotechnology, Inc. · R44 · FY2009 · NS

Characterization of silently HBV-infected hepatocytes in HIV co-infection

$790,717
Ashwin Balagopal · Johns Hopkins University · R01 · FY2018 · AI

Treating flaviviruses with mRNA-encoded Cas13

$790,410
Philip J Santangelo · Emory University · R01 · FY2024 · AI

DAT 18-06 Feasibility and Acceptability of HIV, HCV, and Opioid Use Disorder Services in Syringe Service Programs

$790,403
Bruce R Schackman · Weill Medical Coll Of Cornell Univ · R01 · FY2021 · DA

Sample Processing and Analytical Methods Development for New Anticancer Agents

$790,209
William Douglas Figg · Division Of Clinical Sciences - Nci · ZIC · FY2014 · CA

Development of a charge detection mass spectrometer for the analysis ofgene therapy and other large pharmaceutical biologics

$790,055
Benjamin E Draper · Megadalton Solutions, Inc · R44 · FY2020 · GM

Changes in Bone Quality, Sarcopenia and Fat Distribution in HIV/HCV Patients after HCV Therapy

$790,034
Vincent Lo Re · University Of Pennsylvania · R01 · FY2020 · AI

Understanding the Regional Ecology of a Future HIV Vaccine

$790,033
Dolores Albarracin · University Of Pennsylvania · R01 · FY2024 · MH

NIH Director's Pioneer Award

$790,000
Karla Kirkegaard · Stanford University · DP1 · FY2009 · OD

NIH Director's Pioneer Award

$790,000
Karla Kirkegaard · Stanford University · DP1 · FY2010 · OD

NIH Director's Pioneer Award

$790,000
Karla Kirkegaard · Stanford University · DP1 · FY2008 · OD

SPECS: Safe Pediatric Euglycemia in Cardiac Surgery

$789,648
Michael Agus · Boston Children'S Hospital · R01 · FY2010 · HL

Alcohol Metabolism, Functional Consequences and Apoptosis Signaling Mechanism

$789,531
Byoung-Joon Song · National Institute On Alcohol Abuse And Alcoholism · ZIA · FY2013 · AA

Ohio Valley Node-Network (OVNN) of the NIDA Clinical Trials Network

$789,514
T John Winhusen · University Of Cincinnati · UG1 · FY2015 · DA

Hepatitis C: Studies of Immunity and Pathogenesis

$789,384
Charles M. Rice · Rockefeller University · U19 · FY2007 · AI

NIH Director's Pioneer Award

$789,375
Karla Kirkegaard · Stanford University · DP1 · FY2007 · OD